TN2009000184A1 - Modified soluble fgf receptor fc fusions with improved biological activity - Google Patents

Modified soluble fgf receptor fc fusions with improved biological activity

Info

Publication number: TN2009000184A1
Authority: TN; Tunisia
Prior art keywords: fgf receptor; fusions; biological activity; modified soluble; improved biological
Prior art date: 2006-11-28

Application number

TNP2009000184A

Other languages

English (en)

Inventor

Mark Nesbit

Beatrice Cameron

Francis Blanche

Sylvie Sordello

Celine Nicolazzi

Marc Trombe

Original Assignee

Aventis Pharma Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-28

Filing date

2009-05-08

Publication date

2010-10-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39431092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-05-08 Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa

2010-10-18 Publication of TN2009000184A1 publication Critical patent/TN2009000184A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Zoology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TNP2009000184A 2006-11-28 2009-05-08 Modified soluble fgf receptor fc fusions with improved biological activity TN2009000184A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP06291824		2006-11-28
EP07290042		2007-01-11
PCT/IB2007/004354 WO2008065543A2 (fr)	2006-11-28	2007-11-28	Fusions de fc récepteur de fgf soluble modifié, ayant une activité biologique améliorée

Publications (1)

Publication Number	Publication Date
TN2009000184A1 true TN2009000184A1 (en)	2010-10-18

Family

ID=39431092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2009000184A TN2009000184A1 (en)	2006-11-28	2009-05-08	Modified soluble fgf receptor fc fusions with improved biological activity

Country Status (33)

Country	Link
US (3)	US8119770B2 (fr)
EP (1)	EP2092069B2 (fr)
JP (1)	JP2010510801A (fr)
KR (1)	KR20090102769A (fr)
AR (1)	AR063975A1 (fr)
AT (1)	ATE509106T1 (fr)
AU (1)	AU2007326985C1 (fr)
BR (1)	BRPI0719290A2 (fr)
CA (1)	CA2668932A1 (fr)
CL (1)	CL2007003411A1 (fr)
CO (1)	CO6190564A2 (fr)
CR (1)	CR10777A (fr)
CY (1)	CY1112435T1 (fr)
DK (1)	DK2092069T3 (fr)
EA (1)	EA018700B1 (fr)
EC (1)	ECSP099361A (fr)
GT (1)	GT200900137A (fr)
HR (1)	HRP20110503T1 (fr)
IL (1)	IL198480A0 (fr)
MA (1)	MA31143B1 (fr)
MX (1)	MX2009005692A (fr)
MY (1)	MY145914A (fr)
NI (1)	NI200900097A (fr)
NO (1)	NO20092414L (fr)
PE (1)	PE20081250A1 (fr)
PL (1)	PL2092069T3 (fr)
PT (1)	PT2092069E (fr)
RS (1)	RS51911B (fr)
SI (1)	SI2092069T1 (fr)
SV (1)	SV2009003272A (fr)
TN (1)	TN2009000184A1 (fr)
TW (1)	TW200839012A (fr)
WO (1)	WO2008065543A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1660094A4 (fr)	2003-08-26	2009-09-16	Univ Colorado	Inhibiteurs de l'activite de la protease serine et leurs utilisations dans des methodes et preparations de traitement d'infections bacteriennes
DE602006010874D1 (de)	2005-07-22	2010-01-14	Five Prime Therapeutics Inc	Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
US8338569B2 (en)	2008-08-04	2012-12-25	Five Prime Therapeutics, Inc.	FGFR extracellular domain acidic region muteins
US8445445B2 (en)	2009-09-15	2013-05-21	Five Prime Therapeutics, Inc.	Method of promoting hair growth using FGFR4 extracellular domains
EP2498799B1 (fr) *	2009-11-13	2016-08-17	Five Prime Therapeutics, Inc.	Utilisation de protéines à domaine extracellulaire fgfr1 pour traiter des cancers caractérisés par des mutations activantes ligand-dépendantes dans fgfr2
WO2011084711A2 (fr)	2009-12-17	2011-07-14	Five Prime Therapeutics, Inc.	Procédés favorisant la pousse des cheveux à l'aide des domaines extracellulaires de fgfr3
FR2958936A1 (fr)	2010-04-14	2011-10-21	Sanofi Aventis	Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
AU2011329127B2 (en)	2010-11-15	2015-09-03	Five Prime Therapeutics, Inc.	FGFR1 extracellular domain combination therapies
AU2015258172B2 (en) *	2010-11-15	2017-01-12	Five Prime Therapeutics, Inc.	Fgfr1 extracellular domain combination therapies
US8481038B2 (en)	2010-11-15	2013-07-09	Five Prime Therapeutics, Inc.	Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) *	2010-12-09	2015-02-10	Five Prime Therapeutics, Inc.	FGFR1 extracellular domain combination therapies for lung cancer
PH12013501205A1 (en)	2010-12-23	2013-07-29	Sanofi Sa	Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
AR085302A1 (es)	2011-02-24	2013-09-18	Sanofi Sa	Metodo de produccion de anticuerpos sialilados
CN102219860B (zh) *	2011-05-20	2012-09-12	烟台荣昌生物工程有限公司	FGFR-Fc融合蛋白及其用途
CN102219859B (zh)	2011-05-20	2012-09-12	烟台荣昌生物工程有限公司	拮抗血管新生诱导因子的融合蛋白及其用途
AU2012272636A1 (en)	2011-06-24	2013-05-02	Advent Bio Holdings Llc	Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
UY34317A (es)	2011-09-12	2013-02-28	Genzyme Corp	Anticuerpo antireceptor de célula T (alfa)/ß
HK1202240A1 (en)	2011-11-14	2015-09-25	戊瑞治疗有限公司	Methods of treating cancer
US10478508B2 (en)	2012-01-10	2019-11-19	The Regents Of The University Of Colorado, A Body Corporate	Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EA201591324A1 (ru)	2013-01-16	2016-01-29	Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль)	Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
HK1213180A1 (zh)	2013-03-06	2016-06-30	豪夫迈‧罗氏有限公司	治疗和预防癌症药物抗性的方法
KR102330681B1 (ko)	2013-03-11	2021-11-24	젠자임 코포레이션	당조작을 통한 부위-특이적 항체-약물 접합
US9957313B2 (en)	2013-03-15	2018-05-01	Remegen, Ltd.	FGFR-FC fusion proteins and the use thereof
KR102049990B1 (ko)	2013-03-28	2019-12-03	삼성전자주식회사	c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR20160013092A (ko) *	2013-05-23	2016-02-03	파이브 프라임 테라퓨틱스, 인크.	암을 치료하는 방법
KR20250099279A (ko)	2013-08-01	2025-07-01	파이브 프라임 테라퓨틱스, 인크.	비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체
EP4640239A2 (fr)	2014-03-19	2025-10-29	Genzyme Corporation	Glycoingénierie spécifique à un site de fractions de ciblage
WO2015191986A1 (fr)	2014-06-13	2015-12-17	Genentech, Inc.	Méthodes de traitement et de prévention de la résistance du cancer aux médicaments
KR102777244B1 (ko) *	2015-11-23	2025-03-11	파이브 프라임 테라퓨틱스, 인크.	암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
BR112019023898A2 (pt)	2017-05-16	2020-06-09	Five Prime Therapeutics Inc	método para tratamento de câncer gástrico, uso de um anticorpo e composição
TW201925241A (zh) *	2017-11-30	2019-07-01	美商格里佛診斷方法股份有限公司	用於監測對免疫檢查點抑制劑ｐｄ－１和ｐｄ－ｌ１的抗體治療的免疫測定法和基因工程蛋白
US12448415B2 (en) *	2018-01-04	2025-10-21	Washington University	Compositions and methods for inhibition of alphavirus infection
JP7349995B2 (ja) *	2018-01-26	2023-09-25	ジェネンテック，インコーポレイテッド	ＩＬ－２２Ｆｃ融合タンパク質及び使用方法
EP3947458A1 (fr)	2019-04-03	2022-02-09	Genzyme Corporation	Polypeptides de liaison anti-alpha bêta tcr à fragmentation réduite

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5288856A (en)	1986-11-20	1994-02-22	Pierre Amiguet	Method of isolating acid-stable, biologically active proteins
JP3040121B2 (ja) *	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5750375A (en) *	1988-01-22	1998-05-12	Zymogenetics, Inc.	Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5147638A (en)	1988-12-30	1992-09-15	Oklahoma Medical Research Foundation	Inhibition of tumor growth by blockade of the protein C system
US5288855A (en) *	1989-01-23	1994-02-22	Farmitalia Carlo Erba	Extracellular form of the human fibroblast growth factor receptor
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5153310A (en) *	1989-02-28	1992-10-06	Du Pont Merck Pharmaceutical Company	Il-2 analogs containing n-linked glycosylation sites
CA2063431C (fr)	1989-07-06	2002-10-29	Lewis T. Williams	Recepteurs de facteurs de croisance fibroblastes
ATE131175T1 (de) *	1990-04-27	1995-12-15	Takeda Chemical Industries Ltd	Protein mit fibroblasten-wachstumsfaktor- rezeptoraktivität.
US5349053A (en) *	1990-06-01	1994-09-20	Protein Design Labs, Inc.	Chimeric ligand/immunoglobulin molecules and their uses
DK0538404T3 (da)	1990-07-06	2003-10-13	Rhone Poulenc Rorer Internat H	Fibroblaste vækstfaktorreceptorer
US5541087A (en) *	1994-09-14	1996-07-30	Fuji Immunopharmaceuticals Corporation	Expression and export technology of proteins as immunofusins
US20020045207A1 (en) *	1997-10-31	2002-04-18	Lynne A. Krummen	Glycoprotein production process
DK1071700T3 (da)	1998-04-20	2010-06-07	Glycart Biotechnology Ag	Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
AU3224700A (en) *	1999-02-08	2000-08-25	Chiron Corporation	Fibroblast growth factor receptor-immunoglobulin fusion
US6612152B2 (en) *	1999-05-01	2003-09-02	James E. Keaton	Lifting, servicing, and diagnosing automobiles
US6656738B1 (en) *	1999-11-17	2003-12-02	Bae Systems Integrated Defense Solutions Inc.	Internal heater for preconcentrator
AU2001267337A1 (en) *	2000-06-30	2002-01-14	Maxygen Aps	Peptide extended glycosylated polypeptides
ES2620359T3 (es) *	2000-10-06	2017-06-28	Kyowa Hakko Kirin Co., Ltd.	Células que producen unas composiciones de anticuerpo
US20040132101A1 (en) *	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20040110226A1 (en) *	2002-03-01	2004-06-10	Xencor	Antibody optimization
WO2003085119A1 (fr) *	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Procede d'amelioration de l'activite d'une composition d'anticorps de liaison avec le recepteur fc$g(g) iiia
JPWO2003085118A1 (ja) *	2002-04-09	2005-08-11	協和醗酵工業株式会社	抗体組成物の製造方法
EP2042517B1 (fr) *	2002-09-27	2012-11-14	Xencor, Inc.	Variantes FC optimisées et leurs procédés de génération
JP2007525187A (ja)	2003-05-16	2007-09-06	レセプター・バイオロジクス・インコーポレイテッド	イントロン融合タンパク質、ならびにその同定方法および使用方法
WO2005035741A1 (fr) *	2003-10-09	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	Cellule a genome modifie
DE102004022895A1 (de)	2004-05-10	2005-12-08	Adam Opel Ag	Schallabsorbierendes Verkleidungselement
EP1919950A1 (fr)	2004-07-15	2008-05-14	Xencor, Inc.	Variantes genetiques de fc optimisees
US20060223147A1 (en)	2004-08-05	2006-10-05	Kyowa Hakko Kogyo Co., Ltd.,	Process for producing glycoprotein composition
WO2006047350A2 (fr)	2004-10-21	2006-05-04	Xencor, Inc.	Variants d'immunoglobuline igg a fonction effectrice optimisee
EP1871808A2 (fr)	2005-03-31	2008-01-02	Xencor, Inc.	VARIANTS Fc PRESENTANT DES PROPRIETES OPTIMISEES
US20060234347A1 (en)	2005-04-13	2006-10-19	Harding Thomas C	Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
EP1746161A1 (fr) *	2005-07-20	2007-01-24	Cytheris	IL-7 glycosylée, préparation et utilisations
DE602006010874D1 (de) *	2005-07-22	2010-01-14	Five Prime Therapeutics Inc	Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
WO2007041635A2 (fr)	2005-10-03	2007-04-12	Xencor, Inc.	Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées

2007
- 2007-11-27 PE PE2007001663A patent/PE20081250A1/es not_active Application Discontinuation
- 2007-11-27 CL CL200703411A patent/CL2007003411A1/es unknown
- 2007-11-27 AR ARP070105241A patent/AR063975A1/es not_active Application Discontinuation
- 2007-11-28 CA CA002668932A patent/CA2668932A1/fr not_active Abandoned
- 2007-11-28 TW TW096145220A patent/TW200839012A/zh unknown
- 2007-11-28 SI SI200730682T patent/SI2092069T1/sl unknown
- 2007-11-28 PL PL07866627T patent/PL2092069T3/pl unknown
- 2007-11-28 JP JP2009538805A patent/JP2010510801A/ja active Pending
- 2007-11-28 HR HR20110503T patent/HRP20110503T1/hr unknown
- 2007-11-28 RS RS20110324A patent/RS51911B/sr unknown
- 2007-11-28 MX MX2009005692A patent/MX2009005692A/es active IP Right Grant
- 2007-11-28 WO PCT/IB2007/004354 patent/WO2008065543A2/fr not_active Ceased
- 2007-11-28 DK DK07866627.8T patent/DK2092069T3/da active
- 2007-11-28 US US12/515,463 patent/US8119770B2/en not_active Expired - Fee Related
- 2007-11-28 EA EA200970515A patent/EA018700B1/ru not_active IP Right Cessation
- 2007-11-28 BR BRPI0719290-8A patent/BRPI0719290A2/pt not_active IP Right Cessation
- 2007-11-28 EP EP07866627.8A patent/EP2092069B2/fr active Active
- 2007-11-28 AU AU2007326985A patent/AU2007326985C1/en not_active Ceased
- 2007-11-28 AT AT07866627T patent/ATE509106T1/de active
- 2007-11-28 KR KR1020097013421A patent/KR20090102769A/ko not_active Ceased
- 2007-11-28 PT PT07866627T patent/PT2092069E/pt unknown
- 2007-11-28 MY MYPI20092137A patent/MY145914A/en unknown
2009
- 2009-04-30 IL IL198480A patent/IL198480A0/en unknown
- 2009-05-07 CR CR10777A patent/CR10777A/es not_active Application Discontinuation
- 2009-05-08 TN TNP2009000184A patent/TN2009000184A1/fr unknown
- 2009-05-20 GT GT200900137A patent/GT200900137A/es unknown
- 2009-05-25 EC EC2009009361A patent/ECSP099361A/es unknown
- 2009-05-26 SV SV2009003272A patent/SV2009003272A/es unknown
- 2009-05-26 CO CO09053830A patent/CO6190564A2/es not_active Application Discontinuation
- 2009-05-27 NI NI200900097A patent/NI200900097A/es unknown
- 2009-06-24 MA MA32042A patent/MA31143B1/fr unknown
- 2009-06-24 NO NO20092414A patent/NO20092414L/no not_active Application Discontinuation
2011
- 2011-08-09 CY CY20111100764T patent/CY1112435T1/el unknown
2012
- 2012-01-11 US US13/348,297 patent/US8481487B2/en not_active Expired - Fee Related
2013
- 2013-06-28 US US13/931,184 patent/US20140030265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2007326985A1 (en)	2008-06-05
SV2009003272A (es)	2010-02-05
GT200900137A (es)	2011-09-02
WO2008065543A3 (fr)	2008-08-14
AU2007326985B2 (en)	2013-08-15
EP2092069B2 (fr)	2013-12-18
PE20081250A1 (es)	2008-10-07
MY145914A (en)	2012-05-15
CA2668932A1 (fr)	2008-06-05
US20140030265A1 (en)	2014-01-30
EA200970515A1 (ru)	2009-12-30
US8119770B2 (en)	2012-02-21
RS51911B (sr)	2012-02-29
JP2010510801A (ja)	2010-04-08
WO2008065543A2 (fr)	2008-06-05
ATE509106T1 (de)	2011-05-15
NI200900097A (es)	2010-01-26
NO20092414L (no)	2009-08-21
ECSP099361A (es)	2009-06-30
DK2092069T3 (da)	2011-08-29
TW200839012A (en)	2008-10-01
AR063975A1 (es)	2009-03-04
HRP20110503T1 (hr)	2011-08-31
MA31143B1 (fr)	2010-02-01
US20100061979A1 (en)	2010-03-11
PL2092069T3 (pl)	2011-10-31
CY1112435T1 (el)	2015-12-09
PT2092069E (pt)	2011-07-29
EA018700B1 (ru)	2013-10-30
EP2092069B1 (fr)	2011-05-11
EP2092069A2 (fr)	2009-08-26
SI2092069T1 (sl)	2011-09-30
US20120195851A1 (en)	2012-08-02
CL2007003411A1 (es)	2008-07-04
CR10777A (es)	2009-07-23
CO6190564A2 (es)	2010-08-19
KR20090102769A (ko)	2009-09-30
IL198480A0 (en)	2011-08-01
MX2009005692A (es)	2009-10-12
BRPI0719290A2 (pt)	2014-02-25
US8481487B2 (en)	2013-07-09
AU2007326985C1 (en)	2014-02-20

Publication	Publication Date	Title
TN2009000184A1 (en)	2010-10-18	Modified soluble fgf receptor fc fusions with improved biological activity
MX2009007290A (es)	2009-07-14	Compuestos agonistas del receptor de la proteina 1 similar al glucagon.
MX2013007392A (es)	2013-11-01	Anticuerpo modificado con vida media mejorada.
WO2007146139A3 (fr)	2008-02-28	Molécules d'adn optimisées au niveau des codons codant pour les domaines de liaison avec le récepteur des toxines a et b
WO2008147143A3 (fr)	2009-02-26	Protéines de fusion d'immunoglobuline
WO2005089224A3 (fr)	2007-03-01	Agents arni ciblant le facteur de croissance de l'endothelium vasculaire (vegf)
GB2455449A (en)	2009-06-17	Activatable binding polypeptides and methods of indentifcation and use thereof
WO2013115926A3 (fr)	2013-10-31	Conjugués aspartyl-arnt synthétase-fc
WO2006116260A3 (fr)	2007-02-01	Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine 'charniere'
EP1824872A4 (fr)	2008-11-26	Modulation et utilisations de l'arni de mll-af4
WO2007136893A3 (fr)	2008-05-15	Anticorps anti fgf19 et leurs méthodes d'utilisation
WO2008060705A8 (fr)	2009-11-05	Anticorps anti-dll4 et leurs procédés d'utilisation
WO2009001840A1 (fr)	2008-12-31	Anticorps anti-prominine-1 à activité adcc ou activité cdc
NZ591471A (en)	2012-08-31	Antibodies to ccr2
WO2007112193A3 (fr)	2008-11-20	Conjugués de groupements se liant à la camptothécine
CL2009001258A1 (es)	2010-09-10	Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
WO2008091798A3 (fr)	2008-10-02	Anticorps de ca9 optimises et methodes d'utilisation associees
WO2010066803A3 (fr)	2010-08-19	Anticorps humains du facteur tissulaire
WO2005087810A3 (fr)	2005-11-10	Proteines de fusion dimeres et materiaux et methodes de production de ces proteines
MX2009004167A (es)	2009-09-09	Anticuerpos que enlazan epitopos cxcr7.
ZA202213707B (en)	2024-04-24	Bispecific antibody and use thereof
DOP2009000115A (es)	2010-02-15	Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada
WO2008030564A3 (fr)	2008-09-18	Anticorps aglycosylés et procédés de fabrication et d'utilisation de ces anticorps
ATE498016T1 (de)	2011-02-15	Transposon-system zur gezielten integration
WO2007075899A8 (fr)	2007-11-01	Composes agonistes doubles et leur utilisation